Thr111
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr111  -  eIF2-beta (human)

Site Information
EsDVQEPtEPEDDLD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3181697

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 )
Disease tissue studied:
breast cancer ( 4 , 7 , 8 , 12 ) , breast ductal carcinoma ( 7 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 , 7 ) , cervical cancer ( 31 ) , cervical adenocarcinoma ( 31 ) , gastric cancer ( 16 , 17 , 18 ) , gastric carcinoma ( 16 , 17 , 18 ) , leukemia ( 15 ) , acute myelogenous leukemia ( 15 ) , liver cancer ( 28 ) , lung cancer ( 12 , 23 , 37 ) , non-small cell lung cancer ( 12 , 37 ) , lymphoma ( 9 ) , Burkitt's lymphoma ( 9 ) , follicular lymphoma ( 9 ) , ovarian cancer ( 7 ) , melanoma skin cancer ( 5 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 33 ) , 293E (epithelial) ( 19 ) , A498 (renal) ( 27 ) , breast ( 2 , 7 ) , BT-20 (breast cell) ( 12 ) , BT-549 (breast cell) ( 12 ) , Calu 6 (pulmonary) ( 12 ) , CL1-0 (pulmonary) ( 23 ) , CL1-1 (pulmonary) ( 23 ) , CL1-2 (pulmonary) ( 23 ) , CL1-5 (pulmonary) ( 23 ) , FL-18 (B lymphocyte) ( 9 ) , FL-318 (B lymphocyte) ( 9 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 13 ) , Flp-In T-Rex-293 (epithelial) ( 13 ) , H2009 (pulmonary) ( 12 ) , H2077 (pulmonary) ( 12 ) , H2887 (pulmonary) ( 12 ) , H322M (pulmonary) ( 12 ) , HCC1359 (pulmonary) ( 12 ) , HCC2279 (pulmonary) ( 12 ) , HCC366 (pulmonary) ( 12 ) , HCC4006 (pulmonary) ( 12 ) , HCC78 (pulmonary) ( 12 ) , HCC827 (pulmonary) ( 12 ) , HeLa (cervical) ( 1 , 6 , 11 , 22 , 24 , 34 , 38 , 39 , 40 , 41 , 42 , 43 ) , HeLa S3 (cervical) ( 31 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 8 ) , HMLER ('stem, breast cancer') ( 8 ) , HOP62 (pulmonary) ( 12 ) , HUES-9 ('stem, embryonic') ( 21 ) , Jurkat (T lymphocyte) ( 10 , 20 , 25 , 26 , 29 , 30 , 36 , 44 , 45 ) , K562 (erythroid) ( 11 , 32 ) , KG-1 (myeloid) ( 15 ) , LCLC-103H (pulmonary) ( 12 ) , liver ( 28 ) , LOU-NH91 (squamous) ( 12 ) , MCF-7 (breast cell) ( 4 ) , MDA-MB-231 (breast cell) ( 12 ) , MDA-MB-468 (breast cell) ( 12 ) , MKN-45 (gastric) ( 16 , 17 , 18 ) , NCI-H1299 (pulmonary) ( 37 ) , NCI-H1395 (pulmonary) ( 12 ) , NCI-H1568 (pulmonary) ( 12 ) , NCI-H1648 (pulmonary) ( 12 ) , NCI-H2030 (pulmonary) ( 12 ) , NCI-H2172 (pulmonary) ( 12 ) , NCI-H322 (pulmonary) ( 12 ) , NCI-H460 (pulmonary) ( 12 ) , NCI-H520 (squamous) ( 12 ) , NCI-H647 (pulmonary) ( 12 ) , OCI-ly1 (B lymphocyte) ( 9 ) , ovary ( 7 ) , PC9 (pulmonary) ( 12 ) , Raji (B lymphocyte) ( 9 ) , WM115 (melanocyte) ( 35 ) , WM239A (melanocyte) ( 5 )

Upstream Regulation
Treatments:
ischemia ( 7 ) , metastatic potential ( 23 )

References 

1

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

4

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

5

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

6

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

7

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

8

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

9

Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42
24667141   Curated Info

10

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

11

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

12

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

13

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

14

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

15

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

16

Moritz A (2011) CST Curation Set: 12384; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

17

Moritz A (2011) CST Curation Set: 12385; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

18

Moritz A (2011) CST Curation Set: 12386; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

19

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

20

Guo A (2011) CST Curation Set: 11850; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](D/E)X(D/E) Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CKII Substrate Antibody (polyAb) Cat#: 5808, PTMScan(R) Phospho-CK Substrate Motif (S*/T*D/EXD/E) Immunoaffinity Beads Cat#: 1994
Curated Info

21

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

22

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

23

Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97
20815410   Curated Info

24

Zhou J (2010) CST Curation Set: 10686; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

25

Possemato A (2010) CST Curation Set: 10273; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](D/E)X(D/E) Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CKII Substrate Antibody (polyAb) Cat#: 5808, PTMScan(R) Phospho-CK Substrate Motif (S*/T*D/EXD/E) Immunoaffinity Beads Cat#: 1994
Curated Info

26

Possemato A (2010) CST Curation Set: 9957; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST]
Curated Info

27

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

28

Gu T (2010) CST Curation Set: 9475; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

29

Possemato A (2010) CST Curation Set: 9439; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: T*PP Motif (T*PP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) T*PP Motif (T*PP) Immunoaffinity Beads Cat#: 5758
Curated Info

30

Possemato A (2010) CST Curation Set: 9353; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Pp[ST]
Curated Info

31

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

32

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

33

Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501
19413330   Curated Info

34

Chen Y, et al. (2009) Combined integrin phosphoproteomic analyses and small interfering RNA--based functional screening identify key regulators for cancer cell adhesion and migration. Cancer Res 69, 3713-20
19351860   Curated Info

35

Old WM, et al. (2009) Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell 34, 115-31
19362540   Curated Info

36

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

37

Tsai CF, et al. (2008) Immobilized metal affinity chromatography revisited: pH/acid control toward high selectivity in phosphoproteomics. J Proteome Res 7, 4058-69
18707149   Curated Info

38

Moritz A (2008) CST Curation Set: 5064; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](D/E)X(D/E) Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CKII Substrate Antibody (polyAb) Cat#: 5808, PTMScan(R) Phospho-CK Substrate Motif (S*/T*D/EXD/E) Immunoaffinity Beads Cat#: 1994
Curated Info

39

Moritz A (2008) CST Curation Set: 5065; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](D/E)X(D/E) Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CKII Substrate Antibody (polyAb) Cat#: 5808, PTMScan(R) Phospho-CK Substrate Motif (S*/T*D/EXD/E) Immunoaffinity Beads Cat#: 1994
Curated Info

40

Moritz A (2008) CST Curation Set: 5074; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](D/E)X(D/E) Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CKII Substrate Antibody (polyAb) Cat#: 5808, PTMScan(R) Phospho-CK Substrate Motif (S*/T*D/EXD/E) Immunoaffinity Beads Cat#: 1994
Curated Info

41

Moritz A (2008) CST Curation Set: 5075; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](D/E)X(D/E) Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CKII Substrate Antibody (polyAb) Cat#: 5808, PTMScan(R) Phospho-CK Substrate Motif (S*/T*D/EXD/E) Immunoaffinity Beads Cat#: 1994
Curated Info

42

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

43

Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50
18452278   Curated Info

44

Stokes M (2008) CST Curation Set: 3883; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

45

Stokes M (2008) CST Curation Set: 3885; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info